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Abstract
Background: Primary insomnia is a widespread and refractory disease. Moxibustion therapy for insomnia shows
some advantages compared with conventional therapies. This systematic review and meta-analysis of randomized
controlled trials (RCTs) was conducted to evaluate the effectiveness and safety of moxibustion therapy for insomnia.
Methods: We conducted a comprehensive literature review of the CENTRAL, PubMed, EMBASE, Web of science,
CNKI, VIP, and Wanfang Data databases from their inception to July 2015 for RCTs that compared moxibustion with
western medications, oral Chinese medicine, or other methods of traditional Chinese medicine (TCM) in patients
with primary insomnia. The primary outcome measure was effective rate and secondary outcome measure was
adverse events. Data collection and analysis included risk of bias evaluation, meta-analysis, sensitivity analysis,
publication bias and adverse events analysis according to corresponding criteria.
Results: The study included 22 RCTs (1,971 patients). The quality of the studies was low. The overall meta-analysis
demonstrated that moxibustion was more effective for insomnia than western medications, oral Chinese medicine
and other TCM therapies (RR = 1.17, 95 % CI 1.12 to 1.23, P < 0.00001). Subgroup analyses demonstrated that moxibustion
was more effective for insomnia than western medications (RR = 1.16, 95 % CI 1.09 to 1.24, P < 0.00001), oral Chinese
medicine (RR = 1.11, 95 % CI 1.04 to 1.18, P = 0.002), and other TCM therapies (RR = 1.22, 95 % CI 1.15 to 1.30, P < 0.
00001). There were no serious adverse effects associated with moxibustion therapy for insomnia, and the rate of adverse
events was low.
Conclusion: It is difficult to get the conclusion regarding the effectiveness and safety of moxibustion for primary
insomnia due to insufficient evidence, such as the high risk of bias in the included studies, small sample sizes,
and few reports on adverse effects. Moxibustion should be considered as a novel therapeutic option for
insomnia, and more rigorous clinical trials of moxibustion therapy for insomnia are needed to assess its effects.
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Background
Description of the condition
Insomnia is a sleep disorder characterized by the inability
to fall asleep, sleep loss and poor-quality sleep. Insomnia
is caused by multiple physiological, psychological, and en-
vironmental factors [1–4].
Insomnia is related to the function of the cerebral cortex
and results from mental or nervous tension. Insomnia is
thought to be associated with a group of centrally lo-
cated neurons coupled with dynamic transformation of
neurotransmitters, including norepinephrine (NE) and
5-hydroxytryptamine (5-HT) [5].
In industrialized countries, insomnia is an epidemic
[6–9], where an estimated 40 % of the population suffers
from the disorder [10–16]. An international survey pub-
lished in 2008 estimated the prevalence of insomnia at
23 % in Japan, 31 % in Western Europe, and 56 % in the
United States [17].
Insomnia can lead to memory problems, depression
[18–20], irritability, and an increased risk for cardio-
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cerebrovascular diseases [21–23], such as headache [24],
hypertension [25–27], and heart failure [28]. Insomnia
can decrease an individual’s health-related quality of life
[29], leading to functional impairment while awake
[29–31] and consequences such as automobile-related
accidents [32] and absenteeism [33–37].
However, insomnia remains under-diagnosed and
under-treated. An estimated 47-67 % of individuals
with insomnia do not seek medical attention. Among
those that do attempt to resolve their sleep problems,
only 50–90 % receive treatment [17, 38].
Description of the intervention
Western conventional medicine recommends pharmaco-
logical treatment (such as hypnotic sedative agents) and
cognitive behavioral therapy (CBT) for insomnia [39].
Pharmacological agents are effective for insomnia but
are only recommended for short-term relief. The long-
term use of these medications is associated with adverse
effects such as disturbed sleep architecture, rebound
insomnia, withdrawal effects [40], damage to cerebral
nerves, memory and psychomotor impairment, hypo-
function, dependency, and addiction [41]. For example,
benzodiazepines may cause headaches, nightmares,
daytime fatigue, nausea, confusion, and falls [42]. Z-
drugs can result in bizarre behaviors, dizziness, falls,
and gastrointestinal upset [43].
Evidence from clinical studies supports the use of CBT
for insomnia [44, 45]. However, CBT is not effective
in all patients [46], and access to treatment is limited
[45, 47] because qualified CBT therapists are rare
[48] and expensive [49].
Consequently, insomnia sufferers require alternative
treatments [50, 51]. Moxibustion is a component used in
traditional Chinese medicine (TCM). Some Chinese
studies by randomized controlled trials (RCTs) or clin-
ical observations suggest that the moxibustion has the
potential to be an effective and safe therapy for insom-
nia, such as improving sleep quality, adjusting the brain’s
sleep function, improving symptoms of dreaminess, diz-
ziness, headache, heavy head and poor memory, and
promoting the periodicity from light to deep sleep [52].
How the intervention might work
Modern medicine believes moxibustion modulates neu-
rotransmitters to resist insomnia, thereby improving
sleep quantity [53]. Experiments in rats indicate that
moxibustion protects against chronic stress by acting on
the hippocampal neurons to increase the amount of
brain-derived neurotrophic factor as well as 5-HT and
its metabolites. Holistic healthcare uses moxibustion to
generate far-infrared and near infrared energy to regu-
late dysfunctional organs and build wellbeing [54]. Sus-
pended moxibustion at Baihui can treat nervous system
diseases by improving the blood supply to brain tissue,
increasing the elasticity of blood vessels, and enhancing
the excitability of related sites on the cerebral cortex
[54]. In TCM, moxibustion is thought to regulate qi and
the blood, tonifying healthy qi to eliminate pathogenesis
by means of warming. Moxibustion applied at Bǎihuì can
balance yin and yang, tonify both the heart and the spleen,
dredge blood vessels, and tranquilize [54] mind [5].
Why it is important to do this study
The effectiveness of moxibustion therapy for insomnia
remains controversial; therefore, its application is lim-
ited. There are currently no published systematic reviews
or meta-analyses investigating the effectiveness and
safety of moxibustion therapy for insomnia.
Objective
This systematic review and meta-analysis of randomized
controlled trials (RCTs) was conducted as a rigorous
evaluation of the effectiveness and safety of moxibustion
therapy for insomnia.
Methods
This systematic review and meta-analysis is reported ac-
cording to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [55].
Database and search strategy
Two review authors (SYJ and YJM) independently
searched the Cochrane Central Register of Controlled
Trials (CENTRAL), PubMed, EMBASE, Web of Science,
Chinese National Knowledge Infrastructure (CNKI), VIP
information database, and Wanfang Data Information
Site from their inception to July 2015. Searches were re-
stricted to studies in the English and Chinese languages.
Medline (Pubmed) search strategy:
1. insomnia OR dyssomnia OR sleep OR sleep disorder
OR sleep maintenance OR somnipathy (in full text);
2. moxibustion OR moxa (in full text);
3. clinical trial OR controlled clinical trial OR
randomized controlled trial OR randomized clinical
trial (in full text);
4. #1 AND #2 AND #3
A monthly e-mail alert was set up at the National
Center for Biotechnology Information (NCBI) from the
U.S. National Library of Medicine (NLM) to obtain up-
dates of new publications.
Inclusion criteria
1) RCTs of patients that were dissatisfied with their
quality of sleep;
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2) in which the intervention group included patients
undergoing therapy with different methods of
moxibustion as monotherapy or combination
therapy (including grain-moxibustion, thunder-fire
moxibustion, heat-sensitive moxibustion), and the
control group included patients undergoing therapy
with western medications, or oral Chinese medicine,
or other TCM therapies (including acupoint massage,
point-application, head-needle acupuncture, auricular-
plaster therapy, and acupuncture);
3) The primary outcome measure was the clinical
effective rate. It was a dichotomous outcome and
the overall effectiveness of moxibustion therapy as a
subjective assessment, which was defined as the
proportion of participants who got improved in sleep
quality and was based on response evaluation criteria
used in the treatment of insomnia with TCM. What’s
more, it was reported by trial participants themselves.
For example, clinical therapeutic effect criteria was
categorized as cure, markedly effective, effective, or
ineffective. according to the Guideline for Clinical
Trials of New Patent Chinese medicines
(GCTNPCM) evaluation standards, which define: (1)
clinical cure as sleep time to restore normal sleep
time OR a nighttime sleep duration of < 6 h, deep
sleep, and full of energy after waking up; (2)
markedly effective as significant improvement of
insomnia, sleep time increased < 3 h compared to
previous sleep time and an increase in the depth of
sleep; (3) effective as amelioration in symptoms as
sleep time increased < 3 h compared with the
previous sleep time; and (4) ineffective as no
significant improvement of insomnia OR
deteriorated after treatment [39, 56]. Then the
patients of “cure, markedly effective, effective” were
taken as people who got improved in sleep quality
and the patients of “ineffective” were taken as people
who got unimproved in sleep quality. The total
number of “cure, markedly effective, effective” were
used to calculate effective rate.
Other assessment criteria of clinical therapeutic effect
with comparable definitions were also considered [39].
4) The secondary outcome measure was adverse events
associated with the use of moxibustion therapy for
insomnia. It was reported in the articles or measured
by validated scales, e.g., Health Survey Questionnaire,
Treatment Emergent Symptom Scale (TESS) et al.
5) Only English and Chinese as language selection
Exclusion criteria
1) studies that were not RCTs;
2) patients diagnosed with primary insomnia resulting
from another physiological or psychological disease;
3) trials in special patient populations such as
menopausal women;
4) trials in which moxibustion as combination therapy
was not the only intervention to differ between the
treatment and control group;




Two review authors (SYJ, YJM) independently examined
titles and abstracts to select eligible RCTs. When data-
sets overlapped or were duplicated, only the most recent
information was included. Then the full text of poten-
tially relevant studies was retrieved. Two author re-
viewers (SYJ and YJM) independently examined the full
text records to determine which studies met the inclu-
sion criteria. Disagreements about the study selection
were resolved by discussion with a third review author
(YZM) and consensus.
Data extraction and management
Two review authors (SYJ and YJM) independently ex-
tracted the data from eligible RCTs including details on
the study population, interventions, and outcome mea-
sures. Disagreements about data extraction were re-
solved through discussion with a third review author
(YZM) and consensus.
Assessment of quality of evidence in included studies
The methodological quality of RCTs was assessed inde-
pendently using the Cochrane Handbook for Systematic
Reviews of Interventions [57] from 7 parts, including
random sequence generation, allocation concealment,
blinding of participants and personnel, blinding of out-
come assessments, incomplete outcome data, selective
reporting, and other bias.
Two review authors (SYJ, YJM) independently evalu-
ated the methodological quality of the included articles.
Disagreements about the assessment of quality of evi-
dence in included studies were resolved through discus-
sion with a third review author (YZM) and consensus.
RCTs with fraudulent data of low quality were not in-
cluded in the meta-analysis.
Data analysis
Statistical analyses were performed using Review Man-
ager [Computer program] Version 5.3. (RevMan5.3,
Copenhagen: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2014). Risk ratios (RRs) with
95 % CIs were calculated for dichotomous variables.
A random-effects model was used to pool the studies
with significant heterogeneity, as determined by the in-
consistency index (I2 ≥ 30 %). A fixed effect model was
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used to pool the studies in the absence of substantial
heterogeneity (I2 < 30 %).
Sensitivity analyses were conducted to explore the im-
pact of confounding factors.
Publication bias was comprehensively assessed using
funnel plot by RevMan v5.3. and Begg’s rank correlation
test of asymmetry by stata.13.0. Publication bias was
thought to be insignificant at P > 0.05 [58].
Results
Trial identification
The searches identified 590 articles. Titles and abstracts
were screened, and 77 RCTs were considered potentially
eligible for inclusion. After analyzing the full-text articles
and a risk of bias assessment, 55 RCTs were excluded.
Twenty-two RCTs were found eligible based on our in-
clusion criteria (Fig. 1).
Characteristics of included studies
The characteristics of the 22 included trials (n = 1,971)
were summarized in Table 1. Five trials [54, 59–62]
compared moxibustion with western medications (n =
477; moxibustion: n = 241, control: n = 236) (Table 1a),
six trials [63–68] compared moxibustion with oral
Chinese medicine (n = 533; moxibustion: n = 267, con-
trol: n = 266) (Table 1b), and eleven trials [5, 69–78]
compared moxibustion with other TCM therapies (n =
961; moxibustion: n = 491, control: n = 470) (Table 1c).
Patients included in the 22 trials were 13 [60] -
75 years [59, 67] of age (moxibustion vs. western medi-
cations: range, 13 [60] - 75 years [59]; moxibustion vs.
oral Chinese medicine: range, 18 [66] - 75 years [67]; moxi-
bustion vs. other TCM therapies: range, 18 [71, 78] -
72 years [71]). The overall duration of disease in the 22 in-
cluded trials ranged from 1 week [67] to 30 years [59]
(moxibustion vs. western medications: range, 1 month [60]
to 30 years [59]; moxibustion vs. oral Chinese medicine:
range, 1 week [67] to 16 years [64]; moxibustion vs. other
TCM therapies: range, 1 month [70] to 20 years [73]).
The diagnostic criteria used in the 22 trials included
(1) Chinese classification and criteria for mental disor-
ders 3rd edition (CCMD-3) [5, 60–62, 65–69, 71, 73, 77],
(2) Chinese classification and diagnostic criteria for
mental disorders second edition-revision (CCMD-2-R)
[72, 74], (3) GCTNPCM [63, 66, 75], (4) International
Classification of Disease 10th Version (ICD-10) [60, 61,
63, 70, 71], (5) sleep efficiency calculation of the World
Health Organization (WHO) [54], (6) Criteria of Diagno-
sis and Therapeutic Effects for TCM Disease and Syn-
drome (CDT&ETCMD&S) [59, 65, 67, 72, 78], (7)
Pittsburgh Sleep Quality Index (PSQI) [64], and (8) un-
clear criteria [76].
The treatment duration of the treatment groups
ranged from 10 [54, 68, 72] to 47 days [73] (moxibustion
vs. western medications: range, 10 [54] to 30 days [59];
moxibustion vs. oral Chinese medicine: range, 10 [68] to
32 days [63]; moxibustion vs. other TCM therapies:
range, 10 [72] to 47 days [73]).
In the control groups of the 22 included trials, the
treatment methods included 2 western medications (Es-
tazolam [54, 59, 60, 62], Diazepam plus Oryzanol plus
VB1 [61]), 6 oral Chinese medicine therapies (Sanhuang
Anshen decoction [65], Renshenguipi pill [66], Huatan-
jieyu decoction [68], Tianwangbuxin decoction [63],
Anshen Bunao decoction [67], Anshen Bunao Ye [64]),
and 5 other TCM therapies (head-acupoint massage [75,
77], point-application [76], head-needle acupuncture
[78], auricular-plaster therapy [71, 73], and acupuncture
[5, 69, 70, 72, 74]). The treatment duration of the con-
trol groups ranged from 7 [68] to 47 days [73]: (moxi-
bustion vs. western medications: range, 10 [54] to
30 days [59]; moxibustion vs. oral Chinese medicine:
range, 7 [68] to 30 days [64, 65]; moxibustion vs. other
TCM therapies: range, 10 [72] to 47 days [73]).
The effectiveness of moxibustion was classified ac-
cording to 5 criteria: (1) GCTNPCM [5, 60–63, 66, 67,
70, 72, 74, 75, 77], (2) CDT&ETCMD&S [65], (3) PSQI
[64], (4) WHO sleep efficiency calculation [54, 69, 78],
(5) unclear criteria [59, 68, 71, 73, 76].
The baseline was comparable because there were no
significant differences in gender, age, or disease duration
between the intervention and control groups (P > 0.05).
Risk of bias in included studies
The overall risk of bias in the 22 included trials was high
(Fig. 2).
In 10 trials [5, 60–62, 65, 70, 72, 75, 77, 78], the risk of
bias due to random sequence generation was assessed as
low because a random number table was used. In 12 tri-
als [54, 59, 63, 64, 66–69, 71, 73, 74, 76], the risk of bias
due to random sequence generation was assessed as un-
clear due to insufficient details in the report.
In all 22 trials [5, 54, 59–78], the risk of bias due to al-
location concealment was assessed as unclear due to in-
sufficient details in the report.
In all 22 trials [5, 54, 59–78], the risk of bias due to
blinding of participants and personnel was assessed as
high. Blinding of participants and personnel was never
possible because all the included trials adopted conven-
tional western medications, oral Chinese herbal medi-
cine, or other TCM interventions such as massage, or
acupuncture.
In all 22 trials [5, 54, 59–78], the risk of bias due
to blinding of outcome assessments was assessed as
high because the primary outcome (effective rate)
was reported by trial participants only according to
inclusion criteria and trial participants were never
possible to be blinded.
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In 19 trials [5, 54, 59–64, 67–72, 74–78], the risk of
bias due to incomplete outcome data was assessed as
low because there were no missing data and all expected
outcomes were reported. Three articles [65, 66, 73] were
assessed as having unclear risk because they did not re-
port sufficient detail to let us make sure the baseline was
balanced after dropouts and did not use an intention-to-
treat (ITT) analysis, though the dropouts were less than
20 % in each article.
In all 22 trials [5, 54, 59–78], the risk of bias due to se-
lective reporting was assessed as low because all the tri-
als reported all of the outcomes that they had specified
in their methods and no additional outcomes were
reported.
Fig. 1 Flow chart of literature search. Following the search strategy, 590 articles were identified from medical literature databases, and 77 required
further assessment. Finally, 22 articles were included in this review
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Table 1 Characteristics of trials included in the meta-analysis
a. Moxibustion vs. Western medications




Trial Control Trial Control















40 (M: 18, F: 22);
AGE: 18-63 (mean: 38);
Disease duration: 1.5 m-4y
40 (M: 16; F: 24);


























40 (M: 18, F: 22);
AGE: 25-75;
Disease duration: 0.5y-5 y














Disease duration: 1 m-10 y;
40;
AGE 14-65;
Disease duration:1 m-10 y;
GCTNPCM
b. Moxibustion vs. oral Chinese medicine
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Table 1 Characteristics of trials included in the meta-analysis (Continued)
c. Moxibustion vs. other TCM therapies
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30 (M: 17, F: 13);
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(mean: 43.3 ± 13.8 y);
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AGE: (mean: 42.7 ± 12.4 y);
Disease duration: (mean:
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99 (M: 38, F: 61);
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(mean: 38 ± 13 y);
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(mean: 7.48 ± 4.57 y)
96 (M: 33, F: 63);
AGE: 21-62 y
(mean: 37 ± 12 y);
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(mean: 7.13 ± 4.92 y)
unclear
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(mean: 45 ± 3. 5 y);
Disease duration: 1 m-18 m
(mean: 5.5 ± 4.2 m)
35 (M: 8, F: 27);
AGE: 25-60 (mean: 48 ± 4.
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Disease duration: 1 m-
18 m
(mean: 5.6 ± 0.4 m)
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36 (M: 15, F: 21);
AGE: 19-67 y
(mean:38.9 y);
Disease duration: 6 m-9 y
(mean: 5.3 y);
36 (M: 17, F: 19);
AGE: 20-68 y
(mean:40.6 y);
Disease duration: 5 m-10 y
(mean: 5 y);
GCTNPCM





34 (M: 13, F: 21);
AGE: (mean:40.54 ± 11.27);
Disease duration: (mean: 9.7 ±
2.45 m);
33 (M: 14, F: 19);
AGE: (mean:39.67 ± 11.93);
Disease duration: (mean:
8.47 ± 1.69 m);
Sleep efficiency by
international standard





100 (M: 46, F: 54);
AGE:
(mean: 35.58 ± 9.87);
Disease duration: (mean: 21.59
± 7.87 m);
98 (M: 45, F: 53);
AGE: (mean: 36.67 ± 10.93);
Disease duration:(mean:
22.76 ± 8.39 m);
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Table 1 Characteristics of trials included in the meta-analysis (Continued)
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Twenty-two trials (n = 1,971) conducted in China were included in this study
CCMD-2-R = Chinese classification and diagnostic criteria for mental disorders second edition-revision; CCDM-3 = Chinese classification and criteria for disorders 3rd edition; CDT&ETCMD&S = Criteria of Diagnosis and
Therapeutic Effects for TCM Disease and Syndrome; GCTNPCM = Guideline for Clinical Trials of New Patent Chinese Medicine; ICD-10 = International Classification of Disease, 10th Version; PSQI = Pittsburgh Sleep Quality


















In 19 trials [5, 54, 59–64, 67–72, 74–78], the risk of
bias due to other reasons was assessed as low because
these studies appeared to be free of other sources of
bias. Three articles [65, 66, 73] were assessed as being at
unclear risk because there were no sufficient detail to let
us make sure the baseline was balanced after dropouts.
Effective rate of moxibustion for insomnia
The effective rate of moxibustion for insomnia was de-
scribed in all 22 included trials.
The overall meta-analysis (Fig. 3) demonstrated that
moxibustion was more effective for insomnia than west-
ern medications, oral Chinese medicine and other TCM
therapies (RR = 1.17, 95 % CI 1.12 to 1.23, P < 0.00001).
There was an evidence of significant heterogeneity be-
tween the trials (χ2 = 33.46, P = 0.04, I2 = 37 %) and tests
for subgroup differences showed there were some poten-
tial differences between the groups (χ2 = 4.37, P = 0.11,
I2 = 54.3 %).
The subgroup meta-analysis (Fig. 3) demonstrated that
moxibustion was more effective for insomnia than west-
ern medications [54, 59–62] (RR = 1.16, 95 % CI 1.09 to
1.24, P < 0.00001), oral Chinese medicine [63–68] (RR =
1.11, 95 % CI 1.04 to 1.18, P = 0.002), and other TCM
therapies [5, 69–78] (RR = 1.22, 95 % CI 1.15 to 1.30,
P < 0.00001). There were no evidence of significant
heterogeneity between the trials comparing moxibus-
tion vs. western medications [54, 59–62] (χ2 = 2.14, P =
0.71, I2 = 0 %) and moxibustion vs. other TCM therapies
[5, 69–78] (χ2 = 9.11, P = 0.52, I2 = 0 %). But there was an
evidence of significant heterogeneity between the trials
comparing moxibustion vs. oral Chinese medicine
[63–68] (χ2 = 7.53, P = 0.18, I2 = 34 %).
To account for clinical heterogeneity and subgroup
differences probably arising from the use of different cri-
teria to evaluate the effectiveness of moxibustion therapy
for insomnia, a sensitivity analysis of trials using only
GCTNPCM criteria was conducted. The effectiveness of
moxibustion classified according to GCTNPCM criteria
was described in 12 trials (moxibustion vs. western med-
ications in 3 trials [60–62], moxibustion vs. oral Chinese
medicine in 3 trials [63, 66, 67] and moxibustion vs.
other TCM therapies in 6 trials [5, 70, 72, 74, 75, 77]).
In sensitivity analysis (Fig. 4), the overall meta-analysis
demonstrated that moxibustion was significantly more
effective for insomnia than western medications, oral
Chinese medicine and other TCM therapies (RR = 1.21,
95 % CI 1.14 to 1.28, P < 0.00001). There was no evi-
dence of significant heterogeneity between the trials
(χ2 = 3.15, P = 0.99, I2 = 0 %) and tests for subgroup dif-
ferences showed there were no potential differences be-
tween the groups (χ2 = 1.14, P = 0.57, I2 = 0 %).
In sensitivity analysis (Fig. 4), the subgroup meta-
analysis demonstrated that moxibustion was still more
Fig. 2 Risk of bias in included studies
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Fig. 3 Forest plot and meta-analysis of effective rate
Fig. 4 Forest plot and meta-analysis of effective rate for sensitivity
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effective for insomnia than western medications [60–62]
(RR = 1.24, 95 % CI 1.11 to 1.38, P = 0.0002), oral Chinese
medicine [63, 66, 67] (RR = 1.15, 95 % CI 1.03 to 1.28, P =
0.01), and other TCM therapies [5, 70, 72, 74, 75, 77]
(RR = 1.23, 95 % CI 1.13 to 1.34, P < 0.00001), indicating
that the outcomes of the original meta-analysis are ro-
bust. There were no evidence of significant heterogen-
eity between the trials comparing moxibustion vs.
western medications [60–62] (χ2 = 0.31, P = 0.86, I2 =
0 %), moxibustion vs. oral Chinese medicine [63, 66,
67] (χ2 = 0.51, P = 0.78, I2 = 0 %), moxibustion vs. other
TCM therapies [5, 70, 72, 74, 75, 77] (χ2 = 1.15, P =
0.95, I2 = 0 %).
Publication bias
There was an obvious publication bias (Fig. 5. Begg’s test
Pr = 0.001).
Adverse events
Adverse events associated with moxibustion therapy for
insomnia were described in 3 studies. Wu [59] reported
3 cases of headache, 5 cases of fatigue, 1 case of consti-
pation, and 2 cases of diarrhea in the moxibustion
group, and 53 cases of bitter taste in the mouth, 6 cases
of thirst, 8 cases of myasthenia, 16 cases of drowsiness,
15 cases of vomiting, and 91 cases of abstinence symp-
toms in the estazolam group. Wang [76] reported 1 case
(5.5 %) of aching in the moxibustion plus point-
application group and 1 case of aching, 1 case of nausea,
and 1 case of diarrhea (total 3 cases, 16.5 %) in the
point-application group (p < 0.05). Xu [78] reported 5
cases (8.33 %) of scalp pain in the moxibustion plus
head-needle acupuncture group and 4 cases (7.47 %) of
scalp pain in the head -needle acupuncture group.
Discussion
Summary of results
The results demonstrated that moxibustion was more ef-
fective for insomnia than western medications, oral
Chinese medicine, and other TCM therapies both in the
overall meta-analysis and subgroup meta-analysis. How-
ever, the efficacy of moxibustion therapy for insomnia
cannot be confirmed due to a high risk of bias in the in-
cluded studies and the small sample sizes. Our findings
indicate no serious adverse effects associated with moxi-
bustion therapy for insomnia and a low rate of adverse
events; however, only a small number of studies reported
on the safety of moxibustion.
Quality of the evidence
The results of our study should be interpreted with cau-
tion due to the high risk of bias in the included trials. In
particular, risk of bias due to the random sequence gen-
eration, allocation concealment, blinding of participants,
personnel, and outcome assessments and incomplete
outcome data are considerations. Firstly random se-
quence generation and allocation concealment are im-
portant to prevent selection bias. Trials with inadequate
allocation concealment report, on average, that the inter-
vention is 18 % more “beneficial” than in trials with ad-
equate concealment (95 % CI 5 % to 29 %) [79].
Secondly, blinding of participants, personnel, and out-
come assessments are important to prevent performance
bias and detection bias. Thirdly, as insomniacs are liable
to be anxious and drop out if they feel the treatment
Fig. 5 Funnel plot
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invalid, according to our clinical experience, especially in
a long treatment duration, detailed information about
how to prevent dropouts or whether to use ITT to deal
with data of dropouts plays irreplaceable role when war-
ranting the validity and the reliability of data. But most
of the included study did not report these 4 parts clearly
or rightly.
Limitations
First, diagnostic criteria for insomnia varied between in-
cluded trials. As the objective of this study was to inves-
tigate the effectiveness of moxibustion for insomnia,
subgroup analyses according to diagnostic criteria were
not performed. This is in accordance with other meta-
analyses of TCM for insomnia [39, 80]. Second, overall
risk of bias in the 22 included trials was high. Third, the
included trials relied on different criteria to classify the
effectiveness of moxibustion which could lead to hetero-
geneity between the trials or subgroup differences, and
the number of studies according to different effective-
ness criteria is not enough if we made subgroup. How-
ever, a sensitivity analysis focusing on GCTNPCM
criterion indicated the results of the meta-analysis were
robust. Fourth, there was an obvious publication bias. The
reason may be some Asian countries, including China,
publish an unusually high proportion of positive results
[81]. Fifth only 3 studies pay attention to adverse effect.
Implications
Our data suggest that additional high-quality trials are
warranted to determine the benefits of moxibustion for
insomnia. When designing and reporting future RCTs
on moxibustion for insomnia, we recommend that the
CONSORT 2010 statement [82, 83], which consists of a
25-item checklist to determine trial quality and rigor,
should be used as a guideline. All clinical trials should
be registered prior to the enrollment of the first patient,
according to the International Committee of Medical
Journal Editors statement [84]. Randomization methods
should be clearly described and fully reported. Although
blinding may be difficult, the blinding of patients and
outcome assessors should be attempted. Well-defined
and widely recognized diagnostic or classified criteria,
such as ICD-10 or the CCMD-3, should be employed to
make a precise clinical diagnosis of insomnia and in-
crease comparability between trials. Additionally, be-
cause insomnia is a highly heterogeneous disease and
presents various etiologies and severities, moxibustion is
likely to differentially affect various patient subgroups.
Therefore, future clinical trials should focus on particu-
lar subgroups or include a very large sample size to de-
lineate the effects of moxibustion on different patient
types. Interventions should include appropriately long
treatment periods, treatment frequencies, and follow-up
periods. The severity of insomnia may vary despite the
presence of absence treatment; thus, a longer follow-up
period with serial measurements of outcomes is import-
ant to determine the long-term effects of moxibustion.
Internationally recognized and validated outcome mea-
surements should be consolidated and used consistently.
Appropriate statistical analyses should be carried out for
the baseline data and ITT analysis is recommended in
case of dropouts or withdrawal. Trials should have a suf-
ficiently large sample size, ideally based on formal power
calculations.
Conclusion
It is difficult to get the conclusion regarding the effect-
iveness and safety of moxibustion for primary insomnia
due to insufficient evidence, such as the high risk of bias
in the included studies, small sample sizes, and few re-
ports on adverse effects. Moxibustion should be consid-
ered as a novel therapeutic option for insomnia, and
more rigorous clinical trials of moxibustion therapy for
insomnia are needed to assess its effects.
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